Aspirin for prevention and treatment of venous thromboembolism

Blood Reviews

Volumn 28, Issue 3, 2014, Pages 103-108

  Becattini, Cecilia ^a   Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Apixaban; Aspirin; Dabigatran; Edoxaban; Oral anticoagulants; Pulmonary embolism; Rivaroxaban; Venous thromboembolism; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; ANTICOAGULANT AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; BLOOD; DOUBLE BLIND PROCEDURE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84900844360     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.03.003     Document Type: Article

References (55)

1. Anderson F.A., Wheeler H.B., Goldberg R.J., Hosmer D.W., Patwardhan N.A., Jovanovic B., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism The Worcester DVT Study. Arch Intern Med 1991, 151:933-938.
2. Prandoni P., Lensing A.W., Cogo A., Cuppini S., Villalta S., Carta M., et al. The long term clinical course of acute deep venous thrombosis. Ann Intern Med 1996, 125:1-7.
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008, 45:914-918.
4. Mackman N., Owens P.A. Tissue factor and thrombosis: The clot starts here. Thromb Haemost 2010, 104:432-439.
5. Wang X., Hsu M.Y., Steinbacher T.E., Monticello T.M., Schumacher W.A. Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction. Thromb Res 2007, 119:593-600.
6. Bovill E.G., van der Vliet A. Venous valvular stasis associated hypoxia and thrombosis: what is the link?. Annu Rev Physiol 2011, 73:527-545.
7. von Brühl M.L., Stark K., Steinhart A., Chandraratne S., Konrad I., Lorenz M., et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012, 209:819-835.
8. Brinkmann V., Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007, 5:577-582.
9. Clark S.R., Ma A.C., Tavener S.A., McDonald B., Goodarzi Z., Kelly M.M., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007, 13:463-469.
10. Brill A., Fuchs T.A., Savchenko A.S., Thomas G.M., Martinod K., De Meyer S.F., et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012, 10:136-144.
11. Fuchs T.A., Brill A., Wagner D.D. Neutrophoils extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012, 32:1777-1783.
12. Reitsma P.H., Versteeg H.H., Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 2012, 32:563-568.
13. Van Der Meijden P.E., Van Schilfgaarde M., Van Oerle R., Renné T., ten Cate H., Spronk H.M. Platelet- and erythrocyte-derived microparticles trigger thrombin generation viafactor XIIa. J Thromb Haemost 2012, 10:1355-1362.
14. Aleman M.M., Gardiner C., Harrison P., Wolberg A.S. Differential contributions of monocyte- and platelet-derived microparticles towards thrombin generation and fibrin formation and stability. J Thromb Haemost 2011, 9:2251-2261.
15. Wu K.K., Barnes R.W., Hoak J.C. Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis. Circulation 1976, 53:687-691.
16. Lauw M.N., Bus E.W., van Wulfften Palthe A.F., Coppens M., Homburg C.H., Middeldorp S., et al. Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. Ann Hematol 2012, 91:103-107.
17. Roth G.J., Stanford N., Majerus P.W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975, 72:3073-3076.
18. Loll P.J., Picot D., Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637-643.
19. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975, 72:2994-2998.
20. FitzGerald G.A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B.
21. Patrono C., Andreotti F., Arnesen H., Badimon L., Baigent C., Collet J.P., et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011, 32:2922-2932.
22. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001, 154:485-490.
23. Caccese D., Praticò D., Ghiselli A., Natoli S., Pignatelli P., Sanguigni V., et al. Superoxide anion and hydroxyl radical release by collagen-induced platelet aggregation-role of arachidonic acid metabolism. Thromb Haemost 2000, 83:485-490.
24. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
25. Caudrillier A., Kessenbrock K., Gilliss B.M., Nguyen J.X., Marques M.B., Monestier M., et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 2012, 122:2661-2671.
26. Lapponi M.J., Carestia A., Landoni V.I., Rivadeneyra L., Etulain J., Negrotto S., et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 2013, 345:430-437.
27. Bulut D., Becker V., Mügge A. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol 2011, 89:239-244.
28. American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty. Adopted by the American Academy of Orthopedic Surgeons Board of Directors May 2007 Available at:. http://www.aaos.org/research/guidelines/PE_guideline.pdf.
29. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000, 355:1295-1302.
30. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:381-453.
31. Eikelboom J.W., Karthikeyan G., Fagel N., Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians Guidelines for Venous Thromboembolism Prevention in Hip and Knee Arthroplasty Differ : What Are the Implications for Clinicians and Patients?. Chest 2009, 135:513-520.
32. Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., et al. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e278S-e325S.
33. Anderson D.R., Dunbar M.J., Bohm E.R., Belzile E., Kahn S.R., Zukor D., et al. Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty. A Randomized Trial. Ann Intern Med 2013, 158:800-806.
34. Antiplatelet trialists' collaboration Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994, 308:235-246.
35. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
36. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000, 132:689-696.
37. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
38. Glynn R.J., Ridker P.M., Goldhaber S., Buring J.E. Effect of low-dose aspirin on the occurrence of venous thromboembolism. Ann Intern Med 2007, 147:525-533.
39. The E.S.P.S. 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci 1997, 151:S27-S37.
40. Tsai A.W., Cushman M., Rosamond W.D., Heckbert S.R., Polak J.F., Folsom A.R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002, 162:1182-1189.
41. Sorensen H.T., Horvath-Puho E., Søgaard K.K., Christensen S., Johnsen S.P., Thomsen R.W., et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population based case-control study. J Thromb Haemost 2009, 7:521-528.
42. Kyrle P., Rosendal F., Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010, 376:2032-2039.
43. Heit J.A., Mohr D.N., Silverstein M.D., Petterson T.M., O'Fallon W.M., Melton L.J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000, 160:761-768.
44. Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999, 340:901-907.
45. Agnelli G., Prandoni P., Santamaria M.G., Bagatella P., Iorio A., Bazzan M., et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001, 345:165-169.
46. Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e419S-e494S.
47. Boutitie F., Pinede L., Schulman S., Agnelli G., Raskob G., Julian J., et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011, 342:d3036. 10.1136/bmj.d3036.
48. Agnelli G., Prandoni P., Becattini C., Silingardi M., Taliani M.R., Miccio M., et al. Warfarin optimal duration italian trials investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003, 139:19-25.
49. Steele P. Trial of dipyridamole-aspirin in recurring venous thrombosis. Lancet 1980, 316:8208-8209.
50. Becattini C., Agnelli G., Schenone A., Eichinger S., Bucherini E., Silingardi M., et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012, 366:1959-1967.
51. Brighton T.A., Eikelboom J.W., Mann K., Mister R., Gallus A., Ockelford P., et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012, 367:1979-1987.
52. Agnelli G., Becattini C., Franco L. New oral anticoagulants for the treatment of venous thromboembolism. Best Pract Res Clin Haematol 2013, 26:151-161.
53. Schulman S., Kearon C., Kakkar A.K., Schellong S., Eriksson H., Baanstra D., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013, 368:709-718.
54. Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
55. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Apixaban for extended Treatment of venous thromboembolism. N Engl J Med 2012, 368:699-708.